Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Oklahoma
With
Genentech, Inc.
Ovarian cancer is the leading cause of death from gynecologic cancer in the United States. The high death rate stems from late presentation and tumor that has spread beyond the ovary at the time of diagnoses.
Ovarian cancer typically spreads throughout the peritoneal cavity. Three randomized clinical trial have recently demonstrated the superiority of intraperitoneal(IP) over intravenous platinum based chemotherapy in optimally debulked advance ovarian cancer. The success of Bevacizumab in metastatic colorectal cancer has led to trials evaluating its' efficacy in advanced ovarian cancer. Based on the mechanism of action of Bevacizumab, there may be benefit of extended therapy with this agent.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with stage II and III epithelial ovarian carcinoma, primary peritoneal carcinoma, or ovarian carcinosarcoma.
Adequate bone marrow, renal, and hepatic function
Patients must be entered no more than twelve weeks postoperatively
You may not be if
Patients with epithelial ovarian carcinoma of low malignant potential (borderline carcinomas).
Stage IV or suboptimally debulked disease following primary cytoreductive surgery
Patients who have received prior radiotherapy or chemotherapy.
